Angiogenesis and multiple myeloma: Exploring prognostic potential of adrenomedullin.

Background: Adrenomedullin (AM) is a multifunctional peptide which under basal conditions mainly regulates vasodilation and maintains vascular integrity but is also implicated in the pathogenesis of several malignancies, including multiple myeloma (MM). It has been shown that adrenomedullin is expressed by human myeloma cell lines and that it enhances MM‐driven angiogenesis. However, the clinical impact of AM remains unknown. Materials and Methods: On that basis, we enrolled 32 newly diagnosed multiple myeloma patients (NDMM) and studied the potential of AM as a prognostic biomarker. Results: We report that elevated levels of AM trend with suboptimal treatment response and inferior survival of NDMM patients. [ABSTRACT FROM AUTHOR]

Copyright of Cancer Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)